drugset / Trial / NCT03416270
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
Phase 2
Completed
34 enrolled
University Health Network, Toronto
Merck Sharp & Dohme LLC · collabToronto General Hospital · collabUniversity Medical Center Groningen · collabUniversity of Toronto · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).
Timeline
- Start
- 2018-06-28
- Primary completion
- 2021-04-14
- Completion
- 2021-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ertugliflozin | Unknown | 15 mg | — |